Anteris Technologies Ltd

Equities

AVR

AU0000088841

Medical Equipment, Supplies & Distribution

Market Closed - Australian S.E. Other stock markets 11:40:51 20/05/2024 am IST			5-day change	1st Jan Change
19.55 ^AUD	-0.31%		-4.63%	+2.09%

15/05	Anteris Technologies Completes Valve-in-Valve-in-Valve Procedure with DurAVR	MT
18/04	Anteris Technologies Posts AU$10.6 Million Cash, AU$20.2 Million Net Cash Outflows for Quarter Ended March 31	MT

Anteris Technologies CEO talks A$35 million raise and 2023 milestones

February 16, 2023 at 11:31 pm IST

(via NewsDirect)

Anteris Technologies Ltd (ASX:AVR, OTC:AMEUF) CEO Wayne Paterson speaks with Proactive after announcing the company has secured A$35 million in funding from a placement to various sophisticated and professional investors at an issue price of A$24.00 per share. AVR intends to use the proceeds to advance the clinical development of its DurAVR™ THV, the company’s first-in-class, biomimetic TAVR valve technology for the treatment of aortic stenosis, and general working capital purposes.

Contact Details

Proactive Investors

Jonathan Jackson

+61 413 713 744

jonathan@proactiveinvestors.com

Latest news about Anteris Technologies Ltd

Anteris Technologies Completes Valve-in-Valve-in-Valve Procedure with DurAVR	15/05	MT
Anteris Technologies Posts AU$10.6 Million Cash, AU$20.2 Million Net Cash Outflows for Quarter Ended March 31	18/04	MT
Anteris Technologies Raises AU$23 Million for DurAVR Study	10/04	MT
Anteris Declares Upbeat Results from Human Trials of Heart Valve	13/03	MT
Anteris Technologies Ltd Reports Earnings Results for the Full Year Ended December 31, 2023	28/02	CI
Anteris Technologies Completes Enrollment for Heart Valve Device Study	17/23/17	MT
Anteris Technologies Secures AU$1 Million Tax Rebate for 2022	13/23/13	MT
Anteris Technologies Ltd(ASX:AVR) dropped from S&P Global BMI Index	18/23/18	CI
Anteris Technologies Ltd Reports Earnings Results for the Half Year Ended June 30, 2023	25/23/25	CI
Anteris Technologies Ltd Announces DurAVR THV Demonstrates Exceptional Results in Second Valve-in-Valve Case	14/23/14	CI
Montefiore Enrolls Patients for US Early Feasibility Study for Anteris Technologies' DurAVR THV	09/23/09	MT
Anteris Technologies Announces First Successful Implantation of Duravr? Thv in A Valve-In-Valve Procedure	31/23/31	CI
Anteris Technologies Implants DurAVR THV in Valve-in-Valve Procedure; Shares Jump 3%	31/23/31	MT
Anteris Technologies Validates Efficacy of Aortic Valve Device	09/23/09	MT
Anteris Technologies Secures US Patent for Transcatheter Heart Valve; Shares Rise 4%	17/23/17	MT
Anteris Technologies, v2vmedtech to Develop Heart Valve Repair Device	19/23/19	MT
Anteris Technologies Ltd acquired 30% stake in v2vmedtech, inc. for $0.37 million.	19/23/19	CI
Australian Shares Rise on Mining, IT Boost Ahead of US Inflation Data	12/23/12	MT
Anteris Technologies Secures US Patent for Heart Valve Product; Shares Rise 3%	12/23/12	MT
US FDA Allows Manufacturing to Start at Anteris Technologies' Expanded Production Facility for DurAVR THV	27/23/27	MT
Anteris Technologies Ltd Announces FDA Allows Manufacturing to Begin At Expanded Facility	27/23/27	CI
Anteris Technologies Ltd(ASX:AVR) added to S&P/ASX All Ordinaries Index	20/23/20	CI
Anteris Technologies Ltd Reports Earnings Results for the Full Year Ended December 31, 2022	28/23/28	CI
Anteris Technologies Ltd Auditor Raises 'Going Concern' Doubt	28/23/28	CI
Anteris Technologies Raises AU$35 Million for Heart Valve Development	09/23/09	MT

Chart Anteris Technologies Ltd

Duration

Period

More charts

Company Profile

Anteris Technologies Ltd is an Australia-based structural heart company. The Company is engaged in designing, developing, and commercializing medical devices. The Companyâs lead product, DurAVR, is a transcatheter heart valve (THV) for treating aortic stenosis. DurAVR THV is made using ADAPT tissue, its patented anti-calcification tissue technology. DurAVR THV is a novel first-in-class biomimetic valve made from a single piece of native-shaped tissue. It is designed to mimic the performance of a pre-disease human aortic valve. Its balloon expandable ComASUR Delivery System provides controlled deployment and accurate placement of the DurAVR THV valve, designed to achieve precise alignment with the heartâs native commissures to achieve ideal valve positioning.

Sector

Medical Equipment, Supplies & Distribution

Calendar

29/05/2024 - Annual General Meeting

More about the company

Income Statement Evolution

More financial data

Ratings for Anteris Technologies Ltd

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

19.61 AUD

Average target price

30 AUD

Spread / Average Target

+52.98%

Consensus

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Other Medical Equipment, Supplies & Distribution

	1st Jan change	Capi.
ANTERIS TECHNOLOGIES LTD	+2.09%	25Cr
ABBOTT LABORATORIES	-5.43%	18TCr
MEDTRONIC PLC	+4.30%	11TCr
BECTON, DICKINSON AND COMPANY	-3.09%	6.83TCr
DEXCOM, INC.	+5.86%	5.22TCr
CENCORA, INC.	+8.15%	4.43TCr
HOYA CORPORATION	+6.67%	4.27TCr
METTLER-TOLEDO INTERNATIONAL, INC.	+25.54%	3.25TCr
TERUMO CORPORATION	+20.03%	2.6TCr
WEST PHARMACEUTICAL SERVICES, INC.	+1.00%	2.59TCr

Other Medical Equipment, Supplies & Distribution